X4 Pharmaceuticals

Contributing Author

Recent Articles by X4 Pharmaceuticals

Jun-16	X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA) XFOR GlobeNewswire
Jun-10	X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA XFOR GlobeNewswire
Jun-02	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XFOR GlobeNewswire
May-14	X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress XFOR GlobeNewswire